Máximo Corporán, M.D.

PGY-4 Psychiatry 📚 Voz en 🎧 @lamaximapodcast por #Spotify 👇🏻 MANAGER @SolTaylorRdl

[Máximo Corporán, M.D. @MaximoCorporan]

ANATOMÍA DE HENRY https://t.co/vupZVaQjUs Médicos en proceso @MaximoCorporan La ética médica no siempre se cumple #Wattpad #Medicina

[Máximo Corporán, M.D. @MaximoCorporan]

No todos tenemos privilegios.

[Dr. Carlos Arnaud @carlos_arnaud]

Descubrimiento y aprobación por @FDA de los diferentes #Antidepresivos

Hoy tocó clase de #Psicofarmacología en @TecSaludMX para Residentes de 2do año de #Psiquiatría

[Máximo Corporán, M.D. @MaximoCorporan]

El trastorno depresivo mayor necesita acompañamiento psicoterapéutico y tratamiento psicofarmacológico. No dejes de buscar ayuda, nadie mejora en el aislamiento.

[Máximo Corporán, M.D. @MaximoCorporan]

El amor no nace, se construye.

[Máximo Corporán, M.D. @MaximoCorporan]

No descuiden su salud mental.

[Máximo Corporán, M.D. @MaximoCorporan]

@GawrysSteve La residencia es agotadora.

[Máximo Corporán, M.D. @MaximoCorporan]

Quiero ir a NY por una semana. ☹️

[Máximo Corporán, M.D. @MaximoCorporan]

Necesito dinero.

[Psychiatrist.com @PsychiatristCNS]

Catatonia after stopping clozapine isn't just a coincidence to note — and if a patient is being switched to a drug that works the opposite way on the cholinergic system, it may make things worse before they get better. A "Rounds in the General Hospital" review in PCC lays out the mechanism: clozapine's chronic muscarinic effects can leave receptors upregulated, so abrupt withdrawal may trigger a rebound cholinergic surge — a known but underappreciated trigger for catatonia.

Takeaway: when catatonia follows clozapine withdrawal, restarting clozapine — not adding more antipsychotics — is the treatment of choice. Reserve other agents for cases refractory to lorazepam, clozapine restart, and ECT, and consider ECT early if malignant features (autonomic instability, fever, rigidity) emerge.

Read the full article here -----> https://t.co/DPdJte3gJG

#Psychiatry #ClinicalPsychiatry #Clozapine #Catatonia #Schizophrenia #MentalHealth #PCC #Psychopharmacology #ClinicalReasoning

[NEI Psychopharm @neiglobal]

What’s changing in the way we understand and treat major depressive disorder? Find out August 22 at NEI Saturday Morning Live. Join Dr. Thomas Schwartz for a closer look at the evolving science of MDD, rapid-acting therapies, emerging treatment approaches, and strategies for improving patient outcomes. See what’s on the agenda and register for free: https://t.co/c7Jp2vB0kH

[Máximo Corporán, M.D. @MaximoCorporan]

@vmeducativa No es gratis. ☹️

[NEI Psychopharm @neiglobal]

The U.S. Food and Drug Administration has approved oveporexton, an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 in adults. Read more https://t.co/YguHBO8tCm

[Dr Erik Messamore @ErikMessamoreMD]

Akathisia is a treatable medication side effect that causes an intense feeling of inner restlessness and a strong urge to keep moving. 🧠💊 It can occur with certain psychiatric medications and is often mistaken for anxiety or agitation.

Learn more 👉 https://t.co/sSI93Wdeir

[NEI Psychopharm @neiglobal]

The U.S. Food and Drug Administration has approved centanafadine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in in adults and pediatric patients aged 6 years and older weighing at least 20kg. Centanafadine is a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI). Read more https://t.co/lwZRoTpYSA

[Nicolas Badre @BadreNicolas]

Centanafadine is likely to be approved by the FDA today for ADHD - a first in class NDSRI?

It is an reuptake inhibitor of the main monoamines: serotonin, dopamine, and norepinephrine

It differs from most currently available re-uptake inhibitors, which primarily target:
• serotonin (SSRIs)
• serotonin and norepinephrine (SNRIs)
• norepinephrine and dopamine (NDRIs/bupropion)

There is actually already another NDSRI, but folks don't want to mention it - cocaine. The kinetics make it pretty different though.

As always appropriate caution and skepticism is adequate with new psychotropics. ADHD is still a debated concept. Non-stimulant are much less used than stimulants for ADHD.

Ref for binding affinity- DOI: 10.1002/syn.21538

[Psychiatry Excellence @psycheureka]

Not every psychotic symptom after stopping antipsychotics is relapse.

In some cases, it’s a withdrawal-associated (rebound) psychosis.

Psychotic rebound can occur when D2 blockade is removed before dopamine receptors have readapted. 🧵👇

[Carlos Rebolleda @RebolledaGil]

No todas las vías de la serotonina calman el cerebro; algunas, de hecho, pueden aumentar la ansiedad. Los avances en neurociencia están cambiando nuestra forma de entender la serotonina: no es simplemente una sustancia química asociada al bienestar, sino una compleja red de 👇

[Psychiatry Excellence @psycheureka]

Amisulpride is a selective dopamine D2/D3 receptor antagonist with a unique dose-dependent effect.

At low doses, it enhances dopamine release, acting as an antidepressant.

At higher doses, it blocks postsynaptic D2/D3 receptors, providing antipsychotic effects (Scatton et al., 1997).

Here’s what clinicians need to know about its mechanism, pharmacokinetics, and clinical applications. 🧵👇

[Psychiatry Excellence @psycheureka]

Narcissism is commonly misunderstood as ‘inflated self-worth’.

But clinically, its pathology is often more fragile: 

self-esteem regulation that depends on admiration, approval, status, and external validation. 🧵👇

[Chris Aiken, MD @chrisaikenmd]

Task-force on circadian rhythms in Bipolar is out, and here's how to use it in practice:
https://t.co/kaQCE7g3PL

Includes dark therapy, light therapy, social rhythm therapy, and how to destigmatize bipolar with circadian education (I had small role on paper).